TEVA vs. TAK, ARGX, BNTX, ONC, ITCI, GMAB, SMMT, RDY, ASND, and MRNA
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.04 beat Teva Pharmaceutical Industries' score of 0.19 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Takeda Pharmaceutical has a net margin of 4.53% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Takeda Pharmaceutical's return on equity.
Teva Pharmaceutical Industries presently has a consensus price target of $24.44, suggesting a potential upside of 39.64%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 5.8%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.7%. Teva Pharmaceutical Industries pays out -87.9% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 118.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio.
Teva Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
Teva Pharmaceutical Industries received 1241 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.95% of users gave Teva Pharmaceutical Industries an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.
54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 15 of the 21 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy TEVA Stock Free TEVA Stock Alerts